ERIS Lifesciences Share Price

    NSE
    1685.2
    +1.40 (0.12%)
    ERIS • 01 Jul, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    61.20%

    3Y Annualised Return

    38.03%

    5Y Annualised Return

    30.26%

    The current prices are delayed, login or Open Demat Account for live prices.

    ERIS Lifesciences Stock Performance

    1W Return2.99
    1Y Return61.20
    Today's Low1639.9
    Prev. Close1,683.80
    Mkt Cap (Cr.)22,834.84
    1M Return7.06
    3Y Return156.58
    52-Week High1910
    Open1,683.00
    PE Ratio293.42
    6M Return26.89
    Today's High1692.6
    52-Week Low987.1
    Face Value1

    ERIS Lifesciences Company background

    Founded in: 2007
    Managing director: Amit Indubhushan Bakshi
    Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to Eris Lifesciences Private Limited on February 9, 2007. Further, the Company was converted into a Public Limited cCompany and the name was changed to Eris Lifesciences Limited on February 2, 2017. The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this, it has a portfolio of 112 Mother Brands across therapy areas. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular antidiabetics vitamins gastroenterology and antiinfective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. Its operations are supported by a distribution network of 22 Sales depots, 2,059 Stockists and more than 5,00,000 retail chemists.In 2007, the company launched Eris division focused on cardiology and diabetes segment. In 2008, the company launched Nikkos division focused on gastroenterology and orthopedics segment. In 2009, the company launched Adura division focused on cardiology and diabetes segment. In 2011, the company launched Montana division focused on gynecology and pediatrics segment. In 2012, the company launched Inspira division focused on cardiology segment. In 2014, the company launched Victus division focused on antidiabetes segment. During the year, the company set up manufacturing facility at Assam. In 2015, the company launched Eris 2 division focused on pain management segment.In 2016, the company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited). During the year, the company acquired 100% of the outstanding equity shares of Aprica Healthcare Private Limited and 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited. In 2017, the company acquired the trademarks UNION, REUNION and BON UNION.Eris Lifesciences made its debut on the secondary equity market on 29 June 2017. The stock debuted at Rs 612 on BSE compared with the initial public offer (IPO) price of Rs 603.In October 2017, Eris Lifesciences Ltd (Eris) acquired the entire shareholding of UTH Healthcare Ltd (UTH) for an allcash consideration of Rs 129 million. UTH is largely engaged in the segments of obesity, diabetes, gestational diabetes mellitus, maternal nutrition, and cardiovascular diseases. The acquisition provides Eris with a portfolio of products that complement its other offerings.In December 2017, Eris Lifesciences Ltd (Eris) acquired the Indian branded formulations business of Strides Shasun Ltd (Strides) for an aggregate cash consideration of Rs 5000 crore. With this acquisition, Eris acquired the marketing and distribution rights for India for 130+ brands in the Neurology, Psychiatry, Nutraceuticals and Women Healthcare therapy areas. The Indian branded formulations business being divested by Strides had sales of Rs 181 crore for FY 2017.During the year 2018, capital expenditure amounted to Rs 242.69 million. Additionally, consideration of Rs. 5,061.52 million was paid towards business acquisition.During the year 2018, UTH Healthcare Limited and Eris Healthcare Private Limited (earlier known as Strides Healthcare Private Limited) became subsidiaries of the Company.As on March 31, 2019, the Company has 5 subsidiaries out of which 4 are wholly owned subsidiaries. During the year 2019, capital expenditure amounted to Rs 374.15 million. Additionally, consideration of Rs. 107.22 million was paid towards business acquisition.In April 2019, the Company acquired the remaining shares of Kinedex Healthcare Private Limited, thereby making it a wholly owned subsidiary. It launched new business divisions, ErisART, Nutriverse, Aspire, Oncosciences, Filix, and Allure. A newly constructed facility for softgel was added in the year 2019 with total production capacity of 75 mn units. An extended facility has been included for supplements and Nutraceuticals with an additional capacity of 60 mn tablets, 41 mn capsules and 4 mn sachets. In December 2019, it launched Zomelis, after acquiring the trademark from Novartis.As on March 31, 2020, the Company has 5 five wholly owned subsidiaries. During the year 2020, the Company has acquired the remaining shares of Kinedex Healthcare Private Limited, thereby making it a wholly owned subsidiary. Eris Healthcare Private Limited has incorporated subsidiary company Eris Pharmaceuticals Private Limited on 2nd, June 2020. In Q3 FY 20, the Company launched Rariset, under their inlicensing agreement with Pharmanutra S.P.A for their patent protected Sucrosomial Iron.As on March 31, 2021, the Company has 3 three wholly owned and 1 other than wholly owned subsidiaries. During the year 2021, two Companies namely Aprica Healthcare Limited and Eris Therapeutics Private Limited ceased to be subsidiaries of the Company. Eris Healthcare Private Limited, wholly owned subsidiary of the Company, had incorporated a subsidiary company Eris Pharmaceuticals PrivateLimited on 2nd June, 2020.In FY21. the Company strengthened portfolio with Gluxit, its Dapagliozin brand in the strategically important SGLT 2 segment launched in October20. Eritel and LNBloc maintained ranks in their respective segments and made a debut in fastgrowing antithrombotics segment through the launch of Rivalto, Rivaroxaban offering. It fortified portfolio with the launch of ZACD, an immunityenhancing formulation and added Bricet to its portfolio. Of the top 4 Mother Brands Serlift, Desval ER, Sonaxa and Levroxa while Serlift, and Desval ER maintained theirranks in their respective segments.As on March 31, 2022, the Company has 3 whollyowned subsidiaries and 2 other than wholly owned subsidiaries. In 2022, Eris Therapeutics Limited, wholly owned subsidiary of the Company, was incorporated on 23rd June, 2021. The Companys wholly owned subsidiary Eris M.J. Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited) issued fresh shares through private placement, pursuant to which Eris holding had 70% in Eris M.J. Biopharm Private Limited. It launched human insulin through subsidiary, Eris MJ Biopharm Ltd. In Q4 FY 22, it launched Xsulin in the forms of vials and cartridges.During the year 2023, the Company acquired 100% stake in Eris Oaknet Healthcare Private Limited in 2023. It launched Glura, a DPP4 Inhibitor. In Jan23, it acquired 9 Derma brands from Glenmark for Rs 3,400 million and in Mar23, it acquired 9 Cosmetology brands from Dr Reddys for Rs 2,750 million.In 202223, Eris Healthcare Private Limited, a wholly owned subsidiary, demerged its Acquired Brands business to Aprica Healthcare Limited, a wholly owned subsidiary, through a Scheme of Arrangement effective December 23, 2022.In FY24, Company launched two firstinmarket fixed dose combinations in Oral AntiDiabetes, via Gliclazide + Dapagliflozin and Gliclazide + Sitagliptin in 2024. The new facility in Ahmedabad started commercial operations in March, 2023. The Company initiated Dermatology formulations manufacturing in January 2024. The Company acquired Biocons India Branded Formulation business, thereby completing the second leg of India Injectables strategy in March, 2024. It acquired a 51% stake in Swiss Parenterals Limited, a dossier driven sterile injectable business in February, 2024.

    As of 01 Jul, 2025, ERIS Lifesciences share price is ₹1676.6. The stock opened at ₹1683 and had closed at ₹1683.8 the previous day. During today’s trading session, ERIS Lifesciences share price moved between ₹1,639.90 and ₹1,692.60, with an average price for the day of ₹1666.25. Over the last 52 weeks, the stock has recorded a low of ₹987.10 and a high of ₹1,910.00. In terms of performance, ERIS Lifesciences share price has increased by 25.9% over the past six months and has increased by 61.20% over the last year.

    Read More
    ERIS Lifesciences SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹89,72,273 (+38.03%)

    Daily SIP of 25,000 would have become 89,72,273 in 1 year with a gain of 24,72,273 (+38.03%)

    View details of Market Depth

    ERIS Lifesciences Fundamental

    Market Cap (in crs)

    22,834.84

    Face Value

    1

    Turnover (in lacs)

    1,681.03

    Key Metrics

    Qtr Change %
    69.85% Gain from 52W Low
    20.6
    Dividend yield 1yr %
    Below industry Median
    0.4

    ERIS Lifesciences Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    ERIS Lifesciences Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    705.3 Cr
    727.45 Cr
    738.95 Cr
    719.72 Cr
    550.92 Cr
    ERIS Lifesciences Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    2912 Cr
    2032.96 Cr
    1696.3 Cr
    1373.14 Cr
    1220.57 Cr
    1089.46 Cr
    ERIS Lifesciences Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    102.29 Cr
    86.93 Cr
    96.35 Cr
    89.42 Cr
    79.63 Cr
    ERIS Lifesciences Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    374.61 Cr
    397.05 Cr
    374.16 Cr
    405.79 Cr
    355.14 Cr
    296.51 Cr

    ERIS Lifesciences Result Highlights

    • ERIS Lifesciences Ltd reported a 22.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 40.2%.

    • Its expenses for the quarter were down by 20.5% QoQ and up 49.3% YoY.

    • The net profit decreased 8.4% QoQ and increased 29.5% YoY.

    • The earnings per share (EPS) of ERIS Lifesciences Ltd stood at 5.2 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in ERIS Lifesciences

    Promoter
    54.8%
    Foreign Institutions
    8.4%
    Mutual Funds
    16.6%
    Domestic Institutions
    18.1%
    Public
    18.6%
    Promoter
    54.9%
    Foreign Institutions
    8.4%
    Mutual Funds
    16.5%
    Domestic Institutions
    18%
    Public
    18.7%
    Promoter
    54.9%
    Foreign Institutions
    8%
    Mutual Funds
    17%
    Domestic Institutions
    18.6%
    Public
    18.5%
    Promoter
    54.9%
    Foreign Institutions
    14.6%
    Mutual Funds
    14.5%
    Domestic Institutions
    16.2%
    Public
    14.3%
    Promoter
    54.9%
    Foreign Institutions
    14.3%
    Mutual Funds
    14.9%
    Domestic Institutions
    15.6%
    Public
    15.2%
    Promoter
    54.9%
    Foreign Institutions
    13.1%
    Mutual Funds
    13.8%
    Domestic Institutions
    14.6%
    Public
    17.4%

    ERIS Lifesciences Technical Analysis

    Moving Averages Analysis
    1685.2
    Current Price
    Bullish Moving Averages
    15
    Bearish Moving Averages
    1
    5Day EMA
    1,666.80
    10Day EMA
    1,670.20
    12Day EMA
    1,670.70
    20Day EMA
    1,660.80
    26Day EMA
    1,646.50
    50Day EMA
    1,583.60
    100Day EMA
    1,494.50
    200Day EMA
    1,385.50
    5Day SMA
    1,656.40
    10Day SMA
    1,665.20
    20Day SMA
    1,690.60
    30Day SMA
    1,647.70
    50Day SMA
    1,574.20
    100Day SMA
    1,443.60
    150Day SMA
    1,412.00
    200Day SMA
    1,394.60
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    49870 Rs
    106331 Rs
    Week Rs
    99549 Rs
    201419 Rs
    Month Rs
    129206 Rs
    394349 Rs
    1,669.70
    Pivot
    Resistance
    First Resistance
    1,699.50
    Second Resistance
    1,722.40
    Third Resistance
    1,752.20
    Support
    First Support
    1,646.80
    Second support
    1,617
    Third Support
    1,594.10
    Relative Strength Index
    54.31
    Money Flow Index
    71.38
    MACD
    24.19
    MACD Signal
    38.26
    Average True Range
    70.42
    Average Directional Index
    25.99
    Rate of Change (21)
    7.06
    Rate of Change (125)
    21.09
    Name
    Holding Percent
    Hdfc Small Cap Fund
    7.82
    Franklin India Smaller Companies Fund
    3.37
    Uti-Flexi Cap Fund
    3

    ERIS Lifesciences Latest News

    30 JUN 2025 | Monday

    Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for The Meeting Held On June 30, 2025

    27 JUN 2025 | Friday

    Eris Lifesciences Ltd - 540596 - Closure of Trading Window

    26 JUN 2025 | Thursday

    Eris Lifesciences Ltd - 540596 - Corporate Presentation

    View More

    ERIS Lifesciences Share Price FAQs

    ERIS Lifesciences share price is ₹1685.2 in NSE and ₹1680.1 in BSE as on 1/7/2025.

    ERIS Lifesciences share price in the past 1-year return was 61.19. The ERIS Lifesciences share hit a 1-year low of Rs. 987.1 and a 1-year high of Rs. 1910.

    The market cap of ERIS Lifesciences is Rs. 22834.84 Cr. as of 1/7/2025.

    The PE ratios of ERIS Lifesciences is 293.42 as of 1/7/2025.

    The PB ratios of ERIS Lifesciences is 9.02 as of 1/7/2025

    The Mutual Fund Shareholding in ERIS Lifesciences was 16.59% at the end of 1/7/2025.

    You can easily buy ERIS Lifesciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of ERIS Lifesciences share price is ₹1910 and ₹987.1 as of 1/7/2025.

    Please be aware that ERIS Lifesciences stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    820.30
    -0.05 (-0.01%)
    1,528.40
    +27.80 (+1.85%)
    2,012.10
    +10.60 (+0.53%)
    1,606.80
    +5.00 (+0.31%)
    3,429.70
    -32.30 (-0.93%)
    Top Gainers
    7,496.00
    +254.00 (+3.51%)
    432.25
    +10.75 (+2.55%)
    1,528.40
    +27.80 (+1.85%)
    1,862.50
    +24.20 (+1.32%)
    2,369.50
    +28.40 (+1.21%)
    Top Losers
    2,410.10
    -55.20 (-2.24%)
    1,173.30
    -25.90 (-2.16%)
    696.45
    -10.40 (-1.47%)
    261.00
    -3.15 (-1.19%)
    6,144.00
    -73.50 (-1.18%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -